Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis
- PMID: 32569853
- DOI: 10.1016/j.critrevonc.2020.102984
Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis
Abstract
Background: The most effective regimen is unclear for patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC). We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating only systemic therapy for R/M HNSCC.
Methods: This systematic review followed PRISMA and the Cochrane Collaboration Handbook for Systematic Reviews of Interventions. Endpoints included overall survival (OS), progression-free survival (PFS) and overall response rates (ORR).
Results: 55 RCTs from 1990-November 2019 qualified for review (n=12132). Only PD-1/PDL-1 inhibitors increased OS in R/M HNSCC platinum-resistant disease against their control (HR = 0·79, 95%CI 0·70-0.90, p<0·001), especially for PD-L1 ≥ 1% expressing tumours (HR = 0·72, 95%CI 0·60-0·86, p<0·001). PFS was prolonged for anti-EGFR agents against methotrexate when used in a second line setting (HR = 0·74, 95 %CI 0·62-0·87, p=0·001), and when cetuximab (HR = 0·60, 95%CI 0·49-0·72, p<0·0001) and panitumumab (HR = 0·76, 95%CI 0·65-0·89, p=0·001) were introduced to platinum-based regimens for first-line treatment.
Conclusions: PD-1/PD-L1 inhibitors may represent the future of R/M HNSCC treatment. However, EGFR inhibitors may still play improve clinical outcomes.
Keywords: Antineoplastic Protocols; Head and Neck Neoplasms/therapy; Immunotherapy; Local/therapy; Neoplasm Recurrence; Neoplasms Metastasis.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
Similar articles
-
Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.Radiat Oncol. 2023 Jul 4;18(1):109. doi: 10.1186/s13014-023-02310-8. Radiat Oncol. 2023. PMID: 37403098 Free PMC article.
-
Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.Curr Oncol. 2010 Jun;17(3):37-48. doi: 10.3747/co.v17i3.520. Curr Oncol. 2010. PMID: 20567625 Free PMC article.
-
Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.Cancer Med. 2024 Feb;13(4):e7047. doi: 10.1002/cam4.7047. Cancer Med. 2024. PMID: 38457195 Free PMC article.
-
Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.Int J Cancer. 2018 Jun 1;142(11):2198-2206. doi: 10.1002/ijc.31157. Epub 2017 Nov 27. Int J Cancer. 2018. PMID: 29143328 Review.
-
Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.Expert Rev Anticancer Ther. 2018 Sep;18(9):901-915. doi: 10.1080/14737140.2018.1493925. Epub 2018 Jul 16. Expert Rev Anticancer Ther. 2018. PMID: 29999437 Review.
Cited by
-
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.Front Oncol. 2024 Feb 7;14:1283266. doi: 10.3389/fonc.2024.1283266. eCollection 2024. Front Oncol. 2024. PMID: 38384801 Free PMC article.
-
In vitro models as tools for screening treatment options of head and neck cancer.Front Med (Lausanne). 2022 Sep 7;9:971726. doi: 10.3389/fmed.2022.971726. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36160162 Free PMC article. Review.
-
Induction therapy in recurrent head and neck squamous cell carcinoma: is it time to consider response as a determinant of treatment selection?Transl Cancer Res. 2023 Apr 28;12(4):697-700. doi: 10.21037/tcr-23-59. Epub 2023 Mar 23. Transl Cancer Res. 2023. PMID: 37180661 Free PMC article. No abstract available.
-
Efficacy and Safety of Iodine-125 Brachytherapy in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Onco Targets Ther. 2020 Sep 29;13:9657-9666. doi: 10.2147/OTT.S269626. eCollection 2020. Onco Targets Ther. 2020. PMID: 33061447 Free PMC article.
-
Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma.Biomedicines. 2023 Oct 25;11(11):2887. doi: 10.3390/biomedicines11112887. Biomedicines. 2023. PMID: 38001888 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
